Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Benjamin Lockshin
Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD
At the 2025 Fall Clinical Dermatology meeting in Las Vegas, Nevada, the HCPLive editorial team spoke in an interview with Benjamin Locksin, MD, regarding new tyrosine kinase 2 (TYK2) inhibitors for psoriasis.1 Lockshin, an assistant professor of dermatology at Georgetown University, had co-presented a session at the conference titled ‘Seminar-in-Depth: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’ The team asked him about his session and some of the most notable...
The Future of Plaque Psoriasis Therapy
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 9 Published on: , , Expert dermatologists highlight the future of plaque psoriasis treatment, commenting on advances in therapy as well as increasing access to treatment. Bruce Strober, MD, PhD, FAAD: Ben, what are some of the pipeline therapeutics, future developments that you’re excited about with regard to psoriasis?
Using IL-23 Inhibitors in Clinical Practice for Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 8 Published on: , , Benjamin Lockshin, MD, FAAD; and Jennifer Soung, MD, share their experience with IL-23 inhibitors for the treatment of plaque psoriasis in clinical practice. Bruce Strober, MD, PhD, FAAD: Ben, can you share with me an anecdotal case of success that involves an IL-23 inhibitor, one that really was impactful for you?
Selecting IL-23 Inhibitors for Treating Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 7 Published on: , , Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis. Bruce Strober, MD, PhD, FAAD: So, Ben, this is a tougher question. How do you go about selecting among the various IL-23 inhibitors we have at our disposal?
Shifting the Paradigm for Plaque Psoriasis Therapy
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 6 Published on: , , Expert dermatologists discuss the paradigm shift occurring in the management of plaque psoriasis as a result of the expanded array of treatment options. Bruce Strober, MD, PhD, FAAD: Jennifer, is there a paradigm shift occurring right now that you can foresee that defines how we approach psoriasis in 2023 moving into 2024 or from the way we did in 2015 to [20]18?
Head-to-Head Studies for Plaque Psoriasis Therapies
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 5 Published on: , , Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast. Bruce Strober, MD, PhD, FAAD: Jennifer, we have a lot of head-to-head studies between IL-23 inhibitors and other medications with different mechanisms of action.
Considering Safety of IL-23 Inhibitors for Plaque Psoriasis With The Patient
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 4 Published on: , , Expert dermatologist comments on initiating conversations about the safety of IL-23 inhibitors with patients with plaque psoriasis, highlighting biologic-naive patients.
Efficacy of IL-23 Inhibitors for Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 3 Published on: , , Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment. Bruce Strober, MD, PhD, FAAD: What have we learned about the efficacy of IL-23 inhibitors over the 5 to 7 years we’ve had them on the market?
Approaches to Treating Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 2 Published on: , , Expert dermatologists share how the understanding of the pathophysiology of plaque psoriasis guides approaches to therapy. Bruce Strober, MD, PhD, FAAD: So Ben, we have a lot of different biologics now, more so than ever. There are multiple mechanisms of action [MOAs]. Basically, we understand how to approach psoriasis because we understand the pathophysiology.
Impact of Plaque Psoriasis on Quality of Life
Bruce Strober, MD, PhD, FAAD: Hello and welcome to this HCPLive® Peers & Perspectives [episode] titled “Taking the Path to Clear Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis.” I am Dr Bruce Strober, clinical professor of dermatology at Yale University School of Medicine [in New Haven, Connecticut].
A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
Key words adverse effect atopic dermatitis dupilumab eczema treatment uveitis Abbreviations used: AD (atopic dermatitis), IL (interleukin) Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by the helper T cell type 2 cytokines interleukin 4 (IL-4) and/or IL-13. 1 Gandhi N.A. Bennett B.L. Graham N.M. Pirozzi G. Stahl N. Yancopoulos G.D. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov.
Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial | SKIN The Journal of Cutaneous Medicine
Main Article Content Jonathan I Silverberg Benjamin Lockshin Melinda Gooderham Zhen Chen Abhijit Gadkan Ana B Rossi Keywords Atopic Dermatitis, Biologics, Dupilumab, POEMs, Topical Steroids Abstract Abstract not available. Abstract 0 | Poster PDF Downloads 0 References 1. C harman CR, et al. Arch Dermatol. 2004;140:1513-9. 2. S chmitt J, et al. J Allergy Clin Immunol. 2007;120:1389-98. 3. G erbens LA, et al. Allergy. 2017;72:146-63. 4.
Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL) | SKIN The Journal of Cutaneous Medicine
Main Article Content Jonathan I Silverberg Weily Soong Benjamin Lockshin Abhijit Gadkari Zhen Chen Ashish Bansal Keywords Atopic Dermatitis, Biologics, Dupilimab, Mental Health, Anxiety, Depression Abstract Abstract not available. Abstract 0 | Poster PDF Downloads 0 References 1. Weidinger S, Novak N. Lancet. 2016;387:1109-22. 2. Yu SH, Silverberg JI. J Invest Dermatol. 2015;135:3183-6. 3. Eckert L, et al.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Benjamin
Contact Benjamin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack